Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT-Results of the randomized EORTC Phase III trial 22961

被引：0
|
作者：
Bolla, M.
van Tienhoven, G.
de Reijke, T. M.
van den Bergh, A. C.
van der Meijden, A. P.
Poortmans, P. M.
Gez, E.
Kil, P.
Pierart, M.
Collette, L.
机构：
[1] Ctr Hosp Reg Grenoble, Grenoble, France
[2] Acad Med Ctr, Amsterdam, Netherlands
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] Jeroen Bosch Ziekenhuis, Shertogenbosch, Netherlands
[5] Doctor Bernard Verbeeten Inst, Tilburg, Netherlands
[6] Rambam Med Ctr, Haifa, Israel
[7] Sint Elisabethziekenhuis, Tilburg, Netherlands
[8] EORTC Data Ctr, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5014
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Randomized phase II-III trial of concomitant CT/RT versus TPF followed by concomitant CT/RT in locally advanced squamous cell carcinoma of the head and neck (LASCCHN).: Results of the phase II part of the study
    Ghi, M. G.
    Paccagnella, A.
    Koussis, H.
    Loreggian, L.
    Buffoli, A.
    Morandini, G.
    Bonetti, A.
    Galligioni, E.
    Gardani, G.
    Guaraldi, M.
    Cavallo, G.
    Gaion, F.
    Bonciarelli, G.
    Orlando, A.
    Taino, R.
    Orru, S.
    Tuveri, G.
    Manente, P.
    Ferrazzi, E.
    Villa, B.
    ANNALS OF ONCOLOGY, 2006, 17 : XI86 - XI86
  • [42] Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial
    Andren, O.
    Widmark, A.
    Falt, A.
    Ulvskog, E.
    Davidsson, S.
    Karlsson, C. Thellenberg
    Hjalm-Eriksson, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Report of a multicentre Canadian phase III randomized trial of three months versus eight months neoadjuvant androgen deprivation prior to standard dose radiotherapy for clinically localized prostate cancer
    Crook, J.
    Ludgate, C.
    Malone, S.
    Lim, J.
    Eapen, L.
    Bowen, J.
    Lockwood, G.
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S11 - S11
  • [44] China ARCHES: A multicenter phase III randomized doubleblind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) vs PBO plus ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
    Zhou, F.
    Gongqian, Z.
    Guo, H.
    Hu, Z.
    Zhang, X.
    He, D.
    He, Z.
    Zhang, D.
    Li, Y.
    Kadeerbai, H.
    Liu, Y.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S971 - S971
  • [45] NRG Oncology's GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)
    Zumsteg, Z.
    Karrison, T.
    Michaelson, M. D.
    Tran, P.
    Kudchadker, R.
    Feng, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S546 - S546
  • [46] PHOTON VERSUS FAST-NEUTRON EXTERNAL-BEAM RADIOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED PROSTATE-CANCER - RESULTS OF A RANDOMIZED PROSPECTIVE TRIAL
    RUSSELL, KJ
    CAPLAN, RJ
    LARAMORE, GE
    BURNISON, CM
    MAOR, MH
    TAYLOR, ME
    ZINK, S
    DAVIS, LW
    GRIFFIN, TW
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (01): : 47 - 54
  • [47] Multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation prior to conventional dose radiotherapy for clinically localized prostate cancer
    Crook, JM
    Ludgate, C
    Lim, J
    Malone, S
    Eapen, L
    Perry, G
    Bowen, J
    Robertson, S
    Lockwood, G
    JOURNAL OF UROLOGY, 2004, 171 (04): : 312 - 312
  • [48] SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
    Agarwal, Neeraj
    Tangen, Catherine
    Hussain, Maha H. A.
    Gupta, Shilpa
    Plets, Melissa
    Lara, Primo
    Harzstark, Andrea
    Twardowski, Przemyslaw
    Paller, Channing Judith
    Zylla, Dylan M.
    Zibelman, Matthew R.
    Levine, Ellis Glenn
    Roth, Bruce J.
    Goldkorn, Amir
    Vaena, Daniel A.
    Kohli, Manish
    Crispino, Tony
    Vogelzang, Nicholas J.
    Thompson, Ian Murchie
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
    Chi, Kim N.
    Agarwal, Neeraj
    Bjartell, Anders
    Chung, Byung Ha
    Gomes, Andrea Juliana Pereira de Santana
    Given, Robert W.
    Soto, Alvaro Juarez
    Merseburger, Axel Stuart
    Ozguroglu, Mustafa
    Uemura, Hirotsugu
    Ye, Dingwei
    Deprince, Kris
    Naini, Vahid
    Li, Jinhui
    Cheng, Shinta
    Yu, Margaret K.
    Zhang, Ke
    Larsen, Julie S.
    McCarthy, Sharon Anne
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
    Yokomizo, Akira
    Koga, Hirofumi
    Ito, Kazuto
    Takezawa, Yutaka
    Komiyama, Motokiyo
    Nishimura, Kazuo
    Yonese, Junji
    Hashine, Katsuyoshi
    Masumori, Naoya
    Arai, Gaku
    Saito, Shiro
    Shinohara, Mitsuru
    Shimizu, Nobuaki
    Yamauchi, Atsushi
    Satoh, Takefumi
    Tochigi, Tatsuo
    Kobayashi, Mikio
    Fujimoto, Hiroyuki
    Kakimoto, Ken-ichi
    Fukui, Iwao
    Tsukamoto, Taiji
    Nozaki, Miwako
    Karasawa, Katsuyuki
    Hasumi, Masaru
    Ohtani, Mikinobu
    Ishiyama, Hiromichi
    Kuwahara, Masaaki
    Harada, Masaoki
    Ohashi, Yasuo
    Kotake, Toshihiko
    Kakizoe, Tadao
    Suzuki, Kazuhiro
    Naito, Seiji
    Yamanaka, Hidetoshi
    CANCER MEDICINE, 2021, 10 (10): : 3240 - 3248
12345